Skip to main content
Home
  • About
    • Board of Directors
    • Our Staff
    • Careers
      • Policies
      • Annual Reports
        • 2018 Annual Report
        • 2017 Annual Report
    • Programs
      • COVID-19 Hub
      • IMEDS
        • IMEDS Network Partners
        • IMEDS Research Portfolio
        • IMEDS Steering Committee
      • EA Navigator
      • BD4P
      • FDA Patient Listening Sessions
    • News and Events
      • News
      • Events
      • Annual Public Meeting
        • 2019 Annual Public Meeting
        • 2020 Annual Public Meeting
      • Awards
    • Donate
    • COVID-19
    • facebook
    • twitter
    • linkedin
    • youtube
    Home
    • About
      • Board of Directors
      • Our Staff
      • Careers
      • Policies
      • Annual Reports
    • Programs
      • COVID-19 Hub
      • IMEDS
      • EA Navigator
      • BD4P
      • FDA Patient Listening Sessions
    • News and Events
      • News
      • Events
      • Annual Public Meeting
      • Awards
    • Donate
    • COVID-19

    News and Events

    Breadcrumb

    1. Home
    2. News and Events
    • Announcements
    • Coverage
    • Events
    • Annual Public Meeting
    • Awards
    • What if we captured the spirit and urgency of Covid-19 research to cure cancer?
      In recent months, scientists and policymakers around the globe have rallied together with one common goal: to eliminate Covid-19. Budgets have been revised to funnel money toward research, competitive barriers between scientists and companies have been…
      Read More
    • Vaccine hesitancy part 2: Effective strategies for a human-centered health campaign - Atlantic Council
      Trust is health’s most valuable player COVID-19 has made clear that the politicization of health is incredibly dangerous; the health of billions of individuals is at stake, but so too is trust in pharmaceutical companies, in the scientific process, and …
      Read More
    • Leading Health Care and Infectious Disease Experts Join Together to Discuss COVID-19 Vaccine Safety, Equity and Distribution - Associated Press
      December 17, 2020 (Washington, D.C.) As Americans patiently await their turn for COVID-19 vaccination, a group of leading medical, health equity and public policy experts discussed and answered questions as part of a national briefing today about…
      Read More
    • US Agency Grants Approval of Pfizer's COVID Vaccine And Doses Are Expected in Days - Science Alert
      US regulators have authorised the first coronavirus vaccine for emergency use, marking an inflection point in the pandemic and kicking off what's set to be the largest vaccination campaign in US history.
      Read More
    • Countdown to a Coronavirus Vaccine - The New Yorker
      On a hot afternoon in August, Debbie Honeycutt walked into the crowded waiting room of the Medical Center for Clinical Research, an experimental-treatment facility tucked inside a squat office building in San Diego. She was volunteer number four hundred…
      Read More
    • Michael J. Fox Foundation for Parkinson's Research Honored with Advocacy/Policy Award from Reagan-Udall Foundation for the FDA - PR Newswire
      NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has received the Advocacy/Policy Award from the Reagan-Udall Foundation for the Food and Drug Administration. MJFF is the second organization ever to…
      Read More
    • Surescripts Fireside Chat with Dr. Amy Abernethy, Principle Deputy Commissioner and Acting CIO, FDA
      Tom Skelton, CEO of Surescripts, recently spoke with Dr. Amy Abernethy of the FDA, about the impact of COVID-19 and the evolving data needs of public health.    
      Read More
    • FDA’s Amy Abernethy, Friends of Cancer Research, and The Michael J. Fox Foundation for Parkinson’s Research Honored with Innovations in Regulatory Science Awards
      Honorees to be recognized virtually on December 8, 2020
      Read More
    • We may soon have a COVID-19 vaccine. But will enough people take it? - Reuters
      ZURICH/LONDON (Reuters) - With COVID-19 vaccine trial results looking positive, governments and pharmaceutical firms face their next daunting challenge: convincing the world to get inoculated. Public resistance to vaccines has been much discussed this…
      Read More
    • In Brief - The Cancer Letter
      Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
      Read More
    • Officials clarify military role in coronavirus vaccination amid wariness - Roll Call
      President Donald Trump has often touted the role of the military in distributing a COVID-19 vaccine, but health officials close to the process who are concerned about public distrust are taking pains to say the federal government won’t actually be…
      Read More
    • 2020 Innovations in Regulatory Science Awards Dinner
      Download the full event program View Agenda December 8, 2020
      Read More
    • Black Americans are the most hesitant to get a COVID-19 vaccine - USA Today
      Black Americans distrust the government so much they're not participating in large numbers in COVID-19 clinical trials, and many say they won't get a COVID-19 vaccine – at least not until many others get it. Although the first two large clinical trials…
      Read More
    • Reagan-Udall Foundation for the FDA Secures New Grant from The Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
      The Reagan-Udall Foundation for the FDA has received funding from The Rockefeller Foundation to support the COVID-19 Diagnostics Evidence Accelerator launched earlier this year in collaboration with Friends of Cancer Research. As a science-driven…
      Read More
    • Rushing COVID-19 Vaccination Could Undermine Overall Success, Vaccine Experts Warn FDA - IDSE
      Extraordinary and unusual measures may be needed to rapidly develop and distribute a vaccine against SARS-CoV-2, but those efforts should not compromise the safety and efficacy of any product that reaches the market, according to the FDA Vaccines and…
      Read More
    • ‘There’s only one chance to do this right’—FDA panel wrestles with COVID-19 vaccine issues - Science
      Concerns raised yesterday by an advisory group to the U.S. Food and Drug Administration (FDA) may once again tap the brakes on Operation Warp Speed, the U.S. government’s $10.8 billion push to rapidly move candidate COVID-19 vaccines from concept to…
      Read More
    • Patient Warehousing Emerges As Another COVID-19 Vaccine Confidence Problem - Pink Sheet
      Executive Summary CDC officials designing distribution plans worry some eligible for vaccination may wait for a better product to emerge. Federal officials are now confronting another challenge for the uptake of a potential coronavirus vaccine –…
      Read More
    • FDA advisory committee debates safety and efficacy standards for a coronavirus vaccine - The Washington Post
      Vaccine experts on Thursday rigorously debated the Food and Drug Administration’s planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safety and effectiveness.
      Read More
    • Researchers Find Doubts About COVID-19 Vaccine Among People Of Color - NPR
      The Food and Drug Administration is preparing for the eventual rollout of one or more COVID-19 vaccines — by identifying the concerns that some people have about taking such a vaccine. At a meeting Thursday of experts advising the FDA on COVID-19…
      Read More
    • Facing vaccine doubts, US grapples with building confidence in coronavirus shots - BioPharma Dive
      Dive Brief: The Centers for Disease Control and Prevention does not back mandates that healthcare workers or other essential employees receive COVID-19 vaccines, with a CDC official stating Thursday the agency would prefer instead to "build trust and…
      Read More
    • US faces major hurdles for COVID-19 vaccine distribution: Vaccine advisory committee - MSN
      Any coronavirus vaccine that could be authorized for emergency use by the U.S. Food and Drug Administration (FDA) faces several additional hurdles after completing the final stage of clinical trials. That was the theme of key issues addressed today by…
      Read More
    • FDA Panel Stresses Safety, Diversity, Efficacy for COVID-19 Vax - MedPage Today
      COVID-19 vaccine safety, dueling efficacy standards, and representation of groups from racial and ethnic minorities to children drew focus Thursday at arguably the most watched FDA advisory committee meeting ever.
      Read More
    • CDC distribution roadmap, safety oversight plans, and other takeaways from FDA’s big COVID-19 vaccine meeting - ExBulletin
      In less than a year, scientists around the world have rallied against COVID-19 and developed promising vaccines that could stem the pandemic. Concerns remain, however, and, against this backdrop, senior government experts took over Thursday to discuss…
      Read More
    • Group Of Independent Experts To Advise FDA On Coronavirus Vaccine Approval - WUWM Milwaukee
      It's up to the Food and Drug Administration to decide whether a COVID-19 vaccine is safe and effective enough for public distribution. Today, the agency convened a group of independent experts to offer advice on the way forward. NPR science correspondent…
      Read More
    • In historic Covid-19 adcomm, vaccine experts debate a sea of questions — but offer no clear answers - Endpoints News
      The most widely anticipated and perhaps most widely watched meeting in the FDA’s 113-year history ended late Thursday night with a score of questions and very few answers. Read more
      Read More
    • Confidence still lacking in future COVID-19 vaccines - BioWorld
      With the lack of public trust and confidence the biggest barrier to SARS-CoV-2 vaccines in the U.S., the risk of granting an emergency use authorization (EUA) to a vaccine with safety issues or questionable efficacy could destroy confidence in future FDA…
      Read More
    • Core Concept: The pandemic is prompting widespread use—and misuse—of real-world data - PNAS
      COVID-19 has swept across the world, overwhelming healthcare systems and raising countless questions about how best to diagnose patients, treat infections, save lives, and contain the pandemic. In short order, researchers have launched randomized trials…
      Read More
    • FDA study finds fear and distrust among front-line workers and minority groups around COVID-19 vaccines - Fierce Pharma
      Powerful, illuminating and sobering—that’s the description from a research group summing up its initial listening sessions with front-line workers and minority groups about a vaccine. Tasked with tapping key audiences to learn their questions and…
      Read More
    • What to expect from the official COVID-19 vaccine committee - ABC News
      As the race for an effective COVID-19 vaccine continues, the public will get inside look at one a crucial part of the Food and Drug Administration's decision-making process: the first meeting of its normally obscure advisory committee. Never before has…
      Read More
    • October, no surprise: COVID-19 vax AdComm booked for the 22nd - RAPS
      The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee plans to meet on 22 October to discuss matters related to authorization and licensure of vaccines for COVID-19. No application will be on the docket at…
      Read More
    • FDA Applauds Role of Clinical Trials in Fighting COVID-19 - The Association of Clinical Research Professionals
      “Clinical trials are critical” in the battle against the global COVID-19 pandemic, Amy Abernathy, principal deputy commissioner and acting CIO of the U.S. Food and Drug Administration (FDA), told attendees of the Veeva R&D and Quality Summit on…
      Read More
    • Remarks by Dr. Hahn to the Global Coalition for Regulatory Science Research
      I’m delighted to be with you today for this important meeting of the Global Coalition for Regulatory Science Research.  I only wish that we could be together in person. I want to thank Bill Slikker and his co-chair of the Scientific Program Committee,…
      Read More
    • Expanded access eRequest app allows physicians to submit EA requests online - The Cancer Letter
      The Reagan-Udall Foundation for the FDA, with input from experts at FDA, has introduced an Expanded Access eRequest app to streamline expanded access for individual patients in non-emergency settings. “Time is critical when patients have a serious or…
      Read More
    • Ask the Accelerators: Dr. William Morice of Mayo Clinic Laboratories on RWE and COVID-19 diagnostics - Aetion
      Ask the Accelerators is a series highlighting the perspectives and work of organizations and individuals participating in the COVID-19 Evidence Accelerator. Organized by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) and…
      Read More
    • It Just Got Easier for Physicians to Help Their Patients Gain Access to Investigational Treatments
      When a patient is in need of an important medicine, paperwork and forms are the last thing their physician wants to deal with. In some cases, it’s necessary, but the U.S. Food and Drug Administration is doing everything we can to keep it to a minimum.…
      Read More
    • New Expanded Access eRequest App Allows Physicians to Submit EA Requests Online
      Submitting expanded access requests to FDA just got easier for physicians. The Reagan-Udall Foundation for the FDA, with input from experts at FDA, today launched Expanded Access eRequest to streamline expanded access for individual patients in non-…
      Read More
    • Covid-19 Molecular Diagnostic Testing — Lessons Learned - The New England Journal of Medicine
      On February 4, 2020, the U.S. secretary of health and human services declared that emergency use of diagnostics for SARS-CoV-2 was justified, triggering emergency authority for the Food and Drug Administration (FDA) to grant an emergency use…
      Read More
    • Ask the Accelerators: Dr. Nirosha Lederer on COVID-19’s implications for the future of RWE, and what we’ve learned so far - Aetion
      Ask the Accelerators is a series highlighting the perspectives and work of organizations and individuals participating in the COVID-19 Evidence Accelerator. Organized by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) and…
      Read More
    • UPDATED: Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight - Endpoints News
      Former FDA chief Scott Gottlieb’s favorite real-world evidence platform is getting a new stream of cash, as it nears what will likely be the biggest test of the young company so far. Aetion, the New York health tech startup, has for the second time…
      Read More
    • FDA In Brief: Findings from Real-World Data Study Reveal Higher Risk of Hospitalization and Death Among Cancer Patients with COVID-19, Underscore Health Disparities
      The following quote is attributed to Harpreet Singh, M.D., Associate Director, Cancer in Older Adults and Special Populations, FDA’s Oncology Center of Excellence; and Director, Division of Oncology 2, FDA’s Center for Drug Evaluation and Research:
      Read More
    • FDA’s Ongoing Work to Support and Advance COVID-19 Diagnostic Test Accuracy and Availability
      The U. S. Food and Drug Administration has been proactive and supportive of test development by all comers — including laboratories, and large and small commercial manufacturers — to speed development and to quickly authorize tests that the science…
      Read More
    • Industry Voices—How real-world EHR data are enhancing our understanding of COVID-19 - Fierce Healthcare
      Traditionally, the healthcare industry has moved slowly when embracing new technology innovations. However, over the past few months, it has been forced to rapidly advance to confront the challenges posed by COVID-19. One area that has received…
      Read More
    • FDA to Participate in Covid-19 Diagnostics Evidence Accelerator - Bloomberg Law
      The FDA will participate in the Covid-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project organized by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research. Read more
      Read More
    • HAHN PLEDGES TO EVALUATE FUTURE OF DIAGNOSTICS REGULATION - POLITICO Prescription Pulse
      At a Medical Device Innovation Consortium fireside chat Thursday, FDA Commissioner Stephen Hahn said the agency will take a fresh look at how it regulates diagnostics and digital technologies after the coronavirus pandemic. The FDA will be working to…
      Read More
    • Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says - MedTech Dive
      FDA is upping efforts to incorporate real-world data in evaluation of COVID-19 diagnostics and antibody tests, announcing Thursday participation in a partnership exploring how to use that data to improve testing quality, better inform population testing…
      Read More
    • FDA joins Reagan-Udall, Friends of Cancer Research to form COVID-19 Diagnostics Evidence Accelerator - The Cancer Letter
      FDA is participating in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics.  The accelerator is organized by the Reagan-Udall Foundation for FDA in collaboration with Friends…
      Read More
    • Accelerating the fight against COVID-19 with real-world data on tests - BioCentury
      Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still uncertainty about the accuracy of widely used…
      Read More
    • To expedite progress against COVID-19, a public-private “accelerator” taps into real-world data - The Cancer Letter
      This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.
      Read More
    • FDA joins new, public-private COVID-19 diagnostic research accelerator effort - FierceBiotech
      The FDA has joined a public-private diagnostic research project with the goal of bringing more real-world data to bear against the novel coronavirus, and gauging the accuracy of different kinds of tests. Formed by the Reagan-Udall Foundation and Friends…
      Read More
    • New accelerator to boost real-world COVID-19 diagnostics - Regulatory Focus
      A collaboration to use real-world diagnostics evidence will seek to answer key questions about the novel coronavirus, including epidemiologic patterns, individual risk factors, and characteristics of immunity that might develop after infection with COVID…
      Read More
    • New COVID-19 Diagnostics Evidence Accelerator Applies Real-World Data to Answer Urgent Questions on SARS-CoV-2 Testing
      Today, the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, announced the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder, collaborative project to leverage real-world data in the diagnostic test (e.g…
      Read More
    • US FDA Looking To Real-World Evidence To Fill in Gaps On COVID-19 Vaccines - Pinksheet
      Principal Deputy Commissioner Amy Abernethy suggests FDA may clear a COVID-19 vaccine on smaller than usual clinical datasets and rely on real-world data to fill in the gaps. Abernethy said a new public-private partnership is starting to explore how it…
      Read More
    • The pivotal role of real-world data in a pandemic - Biocentury
      Real-world data is taking on a critical role in the age of COVID-19 drug development, where hasty authorizations are being made on limited datasets and natural history data is being collected in real time. Teams across the industry have stepped up to…
      Read More
    • A New Trend in Drug Development: Leveraging Data from Expanded Access - Cancer Therapy Advisor
      A manuscript detailing this study is under revision and awaiting acceptance by the British Journal of Clinical Pharmacology.  The study was funded using an unrestricted grant from myTomorrows, a global company that connects patients to expanded access…
      Read More
    • WHEN YOU DON’T QUALIFY FOR A CLINICAL TRIAL: EXPANDED ACCESS MIGHT HELP - Triage Cancer
      When dealing with a cancer diagnosis, often times the best form of treatment can be offered through a clinical trial. We de-bunked common myths in this blog post, talking about the benefits of considering clinical trials, in efforts to shift the…
      Read More
    • Real-World Data Partnership On COVID-19: US FDA Drawn To Consistency, Diversity of Aetion's Datasets - Pinksheet
      FDA's Amy Abernethy tells the Pink Sheet that initial priorities are likely to include studying COVID-19 natural history and how patients are faring under various medication regimens. Aetion's ability to perform consistent analyses across a variety of…
      Read More
    • Coronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response
      Today, we are announcing another step in our effort to harness diverse streams of data to understand and respond to COVID-19. The U.S. Food and Drug Administration has entered into an agreement with Aetion to collaborate on advanced analytical techniques…
      Read More
    • FDA Teams Up With Data Company Aetion to Study Virus Progression - Bloomberg Law
      The FDA said Tuesday it’s pairing up with the data company Aetion to research Covid-19 complications and what types of medicines virus patients are taking, which could help researchers learn more about which treatments are effective.
      Read More
    • FDA, partnering with New York health tech firm, seeks to collect ‘real-world’ data on Covid-19 - STAT
      The Food and Drug Administration said Tuesday that it will launch a new research project focused on real-world evidence — data collected by insurance companies, in electronic health records, and in other places in medicine — to learn more about Covid-19…
      Read More
    • A New, Better Normal in Health Care? - National Review
      The COVID-19 crisis has fast-tracked long-contemplated, patient-centric changes in medicine.
      Read More
    • BioCentury This Week: Special Edition - Getting Real about COVID-19 Data
      Amy Abernethy, FDA’s principal deputy commissioner and acting CIO, and Mark McClellan, director of the Duke-Margolis Center for Health Policy at Duke University, described in podcast interviews with BioCentury’s Washington Editor Steve Usdin how the…
      Read More
    • Health, Defense Agencies Should Cooperate to Beat COVID-19 - RealClearHealth
      The U.S. has been trying to contain COVID-19 through testing and social distancing. Now it’s time to kill it. What’s needed is intragovernmental cooperation, something that, sadly, is rare in the nation’s capital. In this case, Congress and the Trump…
      Read More
    • Beyond the Magic Bullet: Medical Progress Is Often Incremental - National Review
      Life won’t completely return to normal while the novel coronavirus remains a threat to health and to life. More than 60,000 Americans have already lost their lives to this virus; while older people seem especially vulnerable, the virus has demonstrated…
      Read More
    • Accelerating the collection of real-world data about COVID-19 - Biocentury
      The Reagan-Udall Foundation and Friends of Cancer Research are trying to put real-world data to use against COVID-19. If there are silver linings to the COVID-19 crisis, one is the way groups and individuals who often have adversarial or competitive…
      Read More
    • Politico Prescription Pulse
      Document Drawer The Reagan-Udall Foundation for the FDA and Friends of Cancer Research launched the COVID-19 Evidence Accelerator, a public-private partnership to use data analytics to understand the virus.
      Read More
    • Real-World Evidence On COVID-19: US FDA Approaching With 'Sense Of Urgency' - Pink Sheet
      "Identifying key questions and core data elements is at the heart of a new initiative launched by the Reagan-Udall Foundation and Friends of Cancer Research. The COVID-19 Evidence Accelerator provides a venue for major data organizations, government and…
      Read More
    • First Look at Gilead Drug Virus Response to Open Data Floodgates - Bloomberg Law
      "A new initiative called the COVID-19 Evidence Accelerator aims to pool ongoing data sources from government and academic researchers, health systems, and private companies to solutions for C
      Read More
    • COVID-19 Evidence Accelerator Leverages Real-World Evidence in FDA’s Response to Global Pandemic
      The Reagan-Udall Foundation for the FDA (Foundation) in collaboration with Friends of Cancer Research (Friends) today announced the COVID-19 Evidence Accelerator, an expansive public-private partnership combining the efforts of academic, government, and…
      Read More
    • One-Stop Resource Helps Patients and Healthcare Providers Link to COVID-19 Clinical Trials and Expanded Access Programs
      To help patients, caregivers, physicians, and other healthcare providers find COVID-19 treatment resources as quickly and easily as possible, the Reagan-Udall Foundation for the FDA today launched the online COVID-19 Treatment Hub.
      Read More
    • Nominations Now Open for 2020 Innovations in Regulatory Science Awards
      Nominations are now open for the 2020 Innovations in Regulatory Science Awards presented annually by the Reagan-Udall Foundation for the Food and Drug Administration. These Awards celebrate outstanding achievement in regulatory science and policy.…
      Read More
    • Reagan-Udall Foundation for the FDA Names Susan Winckler as CEO
      The Reagan-Udall Foundation for the Food and Drug Administration has named Susan C. Winckler, RPh, Esq., former FDA Chief of Staff, as its Chief Executive Officer. She will assume the role on May 1, 2020.
      Read More
    • Food Industry Leader Molly Fogarty Named to Board of Directors
      Molly Fogarty, Senior Vice President of Nestlé in the U.S., has been appointed to the Board of Directors for the Reagan-Udall Foundation for the Food and Drug Administration.
      Read More
    • Nominations now closed
      Read More
    • 2019 Innovations in Regulatory Science Awards Dinner Highlights
      Read More
    • Winners of 2019 Innovations in Regulatory Science Awards Announced
      FDA’s Theresa Mullin, Compassionate Use Advisory Committee, and Cystic Fibrosis Foundation to be Honored with Innovations in Regulatory Science Awards  Honorees to be recognized on December 11 in Washington, DC Washington, DC - The Reagan-Udall…
      Read More
    • Duke's Hernandez Appointed to Reagan-Udall Foundation Board of Directors
      The Reagan-Udall Foundation for the Food and Drug Administration has named Dr. Adrian F. Hernandez to its Board of Directors. Dr. Hernandez brings extensive clinical and research experience to the Foundation’s leadership, having served as the Principal…
      Read More
    • Reagan-Udall Foundation for the FDA invites Nominations for IMEDS Steering Committee
      The Reagan-Udall Foundation for the FDA seeks nominations for key positions on its Steering Committee. Comprised of 12 members, the IMEDS Steering Committee provides oversight and guidance on the operation of IMEDS by advising on strategic direction,…
      Read More
    • 2019 Innovations in Regulatory Science Awards Dinner
      Join leaders in the regulatory field on December 11, 2019, to honor leaders and innovators making a significant impact on America's public health. 6 p.m. - 9 p.m. The Mayflower Hotel  1127 Connecticut Avenue NW Washington, DC 20036 Meet our 2019…
      Read More
    • Repurposing Off-Patent Drugs: Research & Regulatory Challenges
      Join us for an interactive two-day workshop to discuss challenges around repurposing drugs that are already on the market but lack commercial and regulatory incentives for further research and development.
      Read More
    • FDA Eases Access to Unapproved Cancer Drugs - OBR Daily
      "Patients with cancer are treated with drugs already approved by the U.S. Food and Drug Administration (FDA) or with an investigational agent in a clinical trial. But there are some patients who may need access to investigational drugs outside the realm…
      Read More
    • Project Facilitate: FDA’s Plan to Ease Expanded Access to Novel Therapies - The ASCO Post
      The U.S. Food and Drug Administration (FDA) plans to provide oncologists with greater help in acquiring expanded access to investigational therapies. Deemed Project Facilitate, the pilot program was announced at a press briefing during the 2019 ASCO…
      Read More
    • FDA Launches Expanded Access Pilot ‘Project Facilitate’ - Regulatory Focus
      The US Food and Drug Administration (FDA) on Monday launched a new pilot program, dubbed Project Facilitate, aimed at helping physicians complete expanded access requests for cancer patients.  
      Read More
    • FDA, Reagan-Udall launch end-to-end expanded access program for cancer - BioCentury
      FDA's Oncology Center of Excellence and the Reagan-Udall Foundation launched Expanded Access Navigator and Project Facilitate, two separate but coordinated pilot programs to provide patients and physicians with expanded access to oncology drugs. The…
      Read More
    • Enhancements to EA Navigator Improve Patient Access to Investigational Therapies
      Embargoed until 9 a.m. EDT June 3, 2019 Media Inquiries: Lea Ann Browning-McNee, 301-509-1846 Consumer/Provider Inquiries: 202-849-2075   Expanded Access Navigator Improves Patient Access to Investigational Therapies New enhancements make it easier…
      Read More
    • Visit us at DIA Global
      Image Talk to our experts at Booth 625 during the DIA 2019 Global Annual Meeting in San Diego. The Exhibit Hall opens June 24.
      Read More
    • 2019 Annual Public Meeting Highlights
      Read More
    • Sharpless Calls for a Nimble, Flexible, More Efficient US FDA - Pinksheet
      "Sharpless said FDA's organization also must ensure collaboration across disciplines and locations, as well as with outside groups. In a speech to the Reagan-Udall Foundation annual meeting later in the day, though, he acknowledged that outside…
      Read More
    • Sharpless Begins to Learn the Ropes While FDA Center Directors Look to the Future
      Read Zach Brennan’s reference to the Foundation's Annual Public Meeting in his Regulatory Focus™ article:  “Sharpless Begins to Learn the Ropes While FDA Center Directors Look to the Future”
      Read More
    • Wasser Departs Reagan-Udall Foundation for the FDA
      June Wasser Departs Reagan-Udall Foundation for the FDA Amar Bhat, PhD, named Interim Executive Director
      Read More
    • Project Facilitate: Enhancing the Single Patient IND Process for Oncology
      May 16, 2019   |   1:00 PM to 3:30 PM FDA White Oak Campus Building 31, Room 1503 - Great Room, 10903 New Hampshire Avenue Silver Spring, MD 20993 Register Here
      Read More
    • Call for Nominations: Innovations in Regulatory Science Awards
      Reagan-Udall Foundation for the Food and Drug Administration is seeking nominations through June 14, 2019, for its third annual Innovations in Regulatory Science Awards. These Awards honor outstanding achievements of individuals and organizations that…
      Read More
    • 2019 Annual Public Meeting
      Annual Public Meeting Set for May 2, 2019 Each year, the Foundation conducts an annual public meeting to discuss its activities and support of the U.S. Food and Drug Administration. The 2019 Annual Public Meeting will focus on pressing FDA initiatives…
      Read More
    • Report on Leveraging Real-World Treatment Experience from Expanded Access Protocols
      Learn about strategies for Leveraging Real-World Treatment Experience from Expanded Access Protocols in the report from our November public meeting at the FDA White Oak Campus. We brought all the stakeholders together --- patient advocates, physicians,…
      Read More
    • Updated FDA Guidance on Expanded Access
      The FDA updated its guidance to clarify that listing in our Expanded Access Navigator Company Directory satisfies the 21st Century Cures Act requirement of making EA policies readily available. Read "How should we post our expanded access policy?" for…
      Read More
    • CDER 2018 Drug Safety Priorities Report
      New Drug Safety Priorities Report for 2018 highlights CDER’s safety work with a reference to our IMEDS program that "allows public and private entities access to the Sentinel System.”  
      Read More
    • FDA to facilitate access to unapproved drugs
      Biocentury coverage on the FDA’s expanded access program and collaboration with the Reagan-Udall Foundation is available here: https://www.biocentury.com/biocentury/regulation/2018-12-14/how-fda-plans-help-patients-get-expanded-access-unapproved-drugs
      Read More
    • The FDA Sentinel Initiative: An evolving National Resource
      Read The FDA Sentinel Initiative—An Evolving National Resource pubished in New England Journal of Medicine in November 2018 by Platt et al featuring our IMEDS program. 
      Read More
    • Coming soon for Expanded Access Policies
      Updates are coming to expanded access procedures and data use. Read the latest from FDA Law Blog featuring key messages from our public meeting on leveraging expanded acccess data.
      Read More
    • Collecting Data from EA Treatment for Regulatory Submissions Presentation
      Executive Director June Wasser will present Collecting Data from EA Treatment for Regulatory Submissions at the Life Science Compassionate Access Summit at 4:00 pm, Monday, March 18th in Philadelphia. She will focus on:  Defining challenges and…
      Read More
    • 2018 Innovations in Regulatory Science Awards Dinner Highlights
      Read More
    • Expanded Access Data Can Support Approval Decisions, US FDA Says
      Pink Sheet featured an article authored by Kate Rawson which highlights important takeaways from our public meeting, Leveraging Real-World Treatment Experience from Expanded Access Protocols on November 19, 2018 at the FDA White Oak Campus. Find the…
      Read More
    • Reagan-Udall Foundation for the FDA Announces Appointment of Three New Board Members
      The Reagan-Udall Foundation for the Food and Drug Administration expands its leadership with the appointment of three new Board members: Andrew C. von Eschenbach, M.D., former FDA Commissioner; Edward John Allera JD, pharmacist and attorney with…
      Read More
    • Leveraging Real-World Treatment Experience from EA Protocols
      See Event Highlights and Download the Meeting Report  Monday, November 19, 2018   |  10:00 AM to 4:30 PM U.S. Food and Drug Administration White Oak Campus, Building 31, Great Room 10903 New Hampshire Avenue, Silver Spring, MD 20993 
      Read More
    • 2018 Awards Dinner
      The Reagan-Udall Foundation for the FDA honored two longtime U.S. Food and Drug Administration leaders and an independent public-private partnership as the 2018 recipients of the Innovations in Regulatory Science Awards. This year’s Innovations in…
      Read More
    • Winners of 2018 Innovations in Regulatory Science Awards Announced
      We're excited to honor two longtime U.S. Food and Drug Administration leaders and an independent public-private partnership as the 2018 recipients of the Innovations in Regulatory Science Awards to be honored on December 4, 2018.
      Read More
    • Wasser Joins Hands On Classrooms Advisory Panel
      Our Executive Director June S. Wasser has agreed to serve on the advisory panel for a new initiative of the Grocery Manufacturers Association Science and Education Foundation (GMA SEF). In this capacity Wasser will be an external reviewer of the next…
      Read More
    • Expanded Access Programs and Real-World Evidence: Public Meeting
      Expanded access programs, sometimes also called “compassionate use” programs, provide patients with serious or immediately life-threatening diseases or conditions access to investigational products outside of clinical trials
      Read More
    • Real-World Evidence to Increase Value in Health Care
      Mark McClellan and his colleagues at Duke-Margolis Health Policy Center outline how real-world evidence can increase value in health care in this Growth Commentary referencing Reagan-Udall Foundation for the FDA’s IMEDS program.
      Read More
    • Reagan-Udall Foundation at the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)
      During the ICPE conference, our Executive Director, June Wasser, will be discussing the importance of the Foundation’s IMEDS (Innovation in Medical Evidence Development and Surveillance) program, which provides a framework and entry point for private-…
      Read More
    • Call for Nominations to Honor Regulatory Science Leaders
      The Reagan-Udall Foundation for the Food and Drug Administration is pleased to announce the call for nominations for the 2018 Innovations in Regulatory Science Awards. The Foundation will be honoring the leadership and achievements of those whose work…
      Read More
    • 2018 Annual Public Meeting Highlights
      Collaboration and partnership, two key aspects of the Reagan-Udall Foundation for the FDA’s commitment to advancing regulatory science, were on full display when leaders from the FDA, the regulatory science community and the medical community gathered in…
      Read More
    • FDA Commissioner Previews OND Changes at Annual Meeting
      Dr. Scott Gottlieb indicated that the upcoming changes to the FDA Office of New Drugs would likely be in place this summer, when taking questions at the Foundation's Annual Public Meeting in this article from RAPS.
      Read More
    • IMEDS Panel Presentation at DIA Global Annual Meeting 2018
      Stop by booth #622 to learn more about the Foundation and our programs including, Innovation in Medical Evidence Development and Surveillance (IMEDS), the Expanded Access Navigator, and our Fellowship initiative.
      Read More
    • Pre-approval Access Webinar
      The Reagan-Udall Foundation for the FDA's Executive Director, June Wasser, was a presenter on a June 6th webinar sponsored by Johnson & Johnson and NYU Langone Health. She explained how patients use the Foundation's Expanded Access Navigator. The…
      Read More
    • Panel of Commissioners Discuss Evolution of FDA at Foundation's Public Meeting May 4th
      Each year the Foundation conducts an annual meeting, open to the public, to discuss its activities and how it supports FDA. This year's meeting takes place May 4th, from 10 a.m until noon, at the law offices of Alston and Bird (950 F St. NW, Washington,…
      Read More
    • 2018 Annual Public Meeting
      We have reached room capacity so registration to attend the meeting is now closed. We look forward to seeing those who registered before April 19th and thank everyone for your support of the Reagan-Udall Foundation for the FDA. The public is still …
      Read More
    • Press release on Expanded Access Navigator after "right-to-try" vote
      DATELINE: WASHINGTON D.C. - MARCH 22, 2018 Right-To-Try law not a shortcut to investigational drugs – Expanded Access Navigator can reduce confusion. Serious or terminally ill patients hoping House passage of federal Right-To-Try legislation will…
      Read More
    • Navigator presentation at CBI's Expanded Access Programs 2018
      Executive Director June Wasser's talk on the Evolving Scope of the Expanded Access Navigator starts at 11am, Wednesday March 28th and includes an update on its expansion into rare diseases. This year's Expanded Access Programs focus is "Design…
      Read More
    • Rare Disease Day at NIH
      Stop by the foundation's table at NIH's Rare Disease Day on March 1st for a demonstration of the Expanded Access Navigator. It's a website that focused initially on oncology but is adding resources for the rare disease community in 2018.
      Read More
    • FDA News Picks Up on Foundation Fellowships as Workforce Multiplier
      FDA hopes to bolster its scientific staff in 2018 and this piece in FDA News explains how the Reagan-Udall Foundation's upcoming Fellowship program could funnel talented post-docs into the agency it was created to support. 
      Read More
    • Sentinel workshop and next-day training
      New analytic tools and methods enhancements have unlocked access to more diverse sources of data than ever before, improving the quality of evidence for safety surveillance. That’s why each year FDA and key leaders from across the Sentinel System…
      Read More
    • Senator Enzi's Gala Remarks Reach Back to Foundation's Start
      Senator Mike Enzi's remarks reminded attendees that Congress named the Reagan-Udall Foundation for the FDA after two leaders fighting neurodegenerative disorders.
      Read More
    • Press release announcing winners of Innovations in Regulatory Science Awards
      The secret's out, and we're excited to honor the two leaders who will be receiving the inaugural Innovations in Regulatory Science Awards at the Gala December 5th. Here's the press release we shared with media and sponsors.
      Read More
    • Mission and Programs Presentation
      Curious about public-private partnerships and the Reagan-Udall Foundation for the FDA? Happy to schedule a presentation on our history, vision, mission and opportunities.
      Read More
    • 2017 Innovations in Regulatory Science Awards
      Read More
    • Save the Date for 2017 Gala
      Inaugural Reagan-Udall Foundation for the FDA Innovations in Regulatory Science Awards Gala  Image
      Read More
    • FDA Commissioner announces Navigator expansion to Rare Diseases
      In one powerful blog post, Dr. Gottlieb waives requirements to wait for a full convening of IRBs to approve single patient expanded access treatments, announces the future expansion of the Foundation's Navigator to rare diseases and offers clarity on…
      Read More
    • Keynote Address at Indiana Life Sciences Summit
      Find our how the Foundation got its start and where it's headed at the Indiana Life Sciences Summit in Indianapolis. Executive Director June Wasser presents a keynote address on the Foundation's mission and public-private partnerships on Tuesday, 10/10. 
      Read More
    • Innovation Awards Nomination Forms
      Nominations are now being accepted for the Innovations in Regulatory Science Awards. These awards will be presented at the inaugural Innovations in Regulatory Science Awards Gala on December 5th, 2017 at the Kaiser Permanente Center for Total Health in…
      Read More
    • The Expanded Access Navigator to be Featured at Philadelphia's Pre-Approval Access Conference
      Executive Director June Wasser leads a 1:45pm session Tuesday, 9/26 on how the Navigator started and resources it shares with patients and physicians.
      Read More
    • Fox News Tampa's Dr. Jo Calls Navigator an Exciting Advancement
      Dr. Joette Giovinco shared the launch of the Expanded Access Navigator in a Fox Medical Team TV and online report. She credited the FDA and advocacy groups who provided input for the online tool and the clip shows how companies are listing single patient…
      Read More
    • Learn About IMEDS at ICPE in Montreal
      The Foundation welcomes questions and discussion about IMEDS at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management Aug 26-30. Stop by Booth 45 for a personal discussion of IMEDS capabilities.
      Read More
    • Press Release Launching Expanded Access Navigator
      Dateline: Washington, D.C. The Reagan-Udall Foundation for the FDA launches Navigator website to share resources and policies on expanded access to investigational therapies.
      Read More
    • Forbes article explains how the Navigator helps doctors request expanded access
      Saving time is critical for physicians treating seriously ill patients who have exhausted alternatives to expanded access. So Forbes contributor Alison Bateman-House explains how the Navigator spells out timelines in this piece called "How To Try An…
      Read More
    • STAT features Navigator article by Exec. Dir. June Wasser
      In the article, Wasser explains why the FDA asked its foundation to create a public-private partnership launching the Navigator. Legislation like the 21st Century Cures Act and changes in regulation require drug companies to make any expanded access…
      Read More
    • MedPage Today describes the Navigator's 8 steps for expanded access
      This short MedPage article focuses on the Navigator's step-by-step guided experience for patients and physicians: from identifying treatment and exploring clinical trials to seeking IRB approval and treatment/reporting requirements.
      Read More
    • DIA Global Forum article traces roots of IMEDS
      Executive Director June Wasser explains the evolution of IMEDS, the Foundation's public-private, big-data partnership modeled after FDA's Sentinal program.
      Read More
    • Denver Post notes Navigator as an FDA improvement in article about Right-To-Try
      The Post and other publications picked up CQ-Roll Call's Andrew Siddons' analysis of the potential impact of federal Right-To-Try legislation. Read the article here: the Reagan-Udall Foundation and Navigator are part of the concluding paragraphs about…
      Read More
    • FDA Blog kicks off industry coverage of Navigator launch
      Read More
    • Susan G. Komen calls Navigator a lifeline
      In this article, Interim President and CEO Ellen Willmot shares her hope that the Navigator will make it easier for breast cancer physicians and patients to apply for, and benefit from, expanded access to investigational treatments
      Read More
    • Navigator's Oncology Focus Cited by ASCO
      The American Society of Clinical Oncology helped develop the Navigator and in this post describes it as a clearinghouse for the single-patient expanded access policies of dozens on leading biopharmaceutical companies. 
      Read More
    • The Health Care Blog Shares Uses for Navigator
      This post points out that the Navigator will expand from an oncology focus to other therapeutic areas in the future, and walks through a hypothetical Zika case where clear expanded access information would be critical.
      Read More
    • Pharmaceutical Commerce links Gottlieb to Navigator's aims
      This magazine article says the Navigator streamlines information-gathering and links the launch to FDA Commissioner Scott Gottlieb's statements that the expanded access process should be less expensive and time-consuming.
      Read More
    • Biotech-Now Urges Companies to Use Navigator Directory
      This blog from the Biotechnology Innovation Organization reminds companies they can comply with the 21st Century Cures Act’s requirements to make their expanded access policy publicly available by listing it on the Expanded Access Navigator's Company…
      Read More
    • Infodocket Credits Team Effort for Navigator
      Quoting the FDA Voice Blog, this online post mentions the Navigator's public-private partners who help guide patients and physicians through the expanded access process.
      Read More

    Support the Reagan-Udall Foundation for the FDA

    Donate
    (202) 849 - 2075
    1900 L Street NW, Suite 835
    Washington, DC 20036
    admin@reaganudall.org
    • facebook
    • twitter
    • linkedin
    • youtube

    © Reagan-Udall Foundation for the FDA
    © Reagan-Udall Foundation for the FDA